Can I Take Vitamin B6 with AOD-9604?

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide spanning amino acid positions 176 to 191 of the human growth hormone (hGH) sequence. Researchers isolated this fragment because it reproduces the fat-mobilizing activity of hGH without detectable binding to the IGF-1 receptor, which means it does not carry the insulin-resistance or proliferative concerns tied to full-length hGH administration [1].

Mechanism of Action

The peptide acts on beta-3 adrenergic receptors in adipose tissue, stimulating lipolysis and inhibiting lipogenesis. A 2001 study by Heffernan et al. Published in the American Journal of Physiology confirmed that the 176-191 fragment retains the lipolytic properties of the full hGH molecule without inducing diabetogenic effects in obese rodent models [2]. The peptide is administered subcutaneously or orally, depending on the compounding formulation, and has a plasma half-life estimated at under 30 minutes after subcutaneous injection based on preclinical pharmacokinetic modeling.

Regulatory Standing

AOD-9604 is not FDA-approved for any human indication. In the United States, it is compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act by licensed compounding pharmacies. The FDA's bulk substances list and ongoing regulatory updates govern which peptides may be compounded; prescribers and patients should confirm current status before initiating therapy [3]. In Australia, the Therapeutic Goods Administration granted AOD-9604 "Generally Recognized as Safe" (GRAS) status in 2014 for oral use in food products, which is sometimes cited in marketing materials but does not constitute clinical approval [4].

What Vitamin B6 Does in the Body

Vitamin B6 is a water-soluble B vitamin that exists in six interconvertible forms. Pyridoxal-5-phosphate (P5P) is the biologically active coenzyme form. It participates in over 100 enzyme reactions, including amino acid transamination, neurotransmitter synthesis (serotonin, dopamine, GABA), and heme biosynthesis [5].

Absorption and Metabolism

Dietary B6 from food and most supplements is absorbed in the jejunum and converted to P5P primarily in the liver. Plasma half-life of P5P is roughly 25 days when bound to albumin. At supplemental doses below 100 mg/day, saturation kinetics keep plasma P5P within physiological ranges. Above 200 mg/day, free (unbound) pyridoxine accumulates and is directly neurotoxic to dorsal root ganglia [6].

The NIH Upper Intake Level

The National Institutes of Health Office of Dietary Supplements sets the Tolerable Upper Intake Level (UL) for vitamin B6 in adults at 100 mg/day [5]. This figure is conservative by design. The primary basis for the UL is a 1997 case series by Dalton and Dalton documenting sensory neuropathy in women taking 117 to 2,840 mg/day for premenstrual syndrome. Full neurological recovery occurred in most patients after discontinuation, but partial deficits persisted in a minority [7].

Does Vitamin B6 Interact with AOD-9604?

No pharmacokinetic interaction between vitamin B6 and AOD-9604 has been identified in published literature, and the mechanistic rationale for one is weak.

Why a Direct Interaction Is Unlikely

AOD-9604 is a short-chain peptide. It is cleared primarily by proteolytic degradation, not by CYP450 hepatic enzymes, UGT transferases, or P-glycoprotein transporters. Vitamin B6 metabolism, by contrast, involves alkaline phosphatase and pyridoxamine 5-phosphate oxidase. These two metabolic pathways do not share rate-limiting enzymes or transporter proteins at any clinically meaningful step [5][6].

From a pharmacodynamic standpoint, B6 does not act on beta-3 adrenergic receptors, IGF-1 signaling, or adipokine pathways that AOD-9604 is proposed to modulate. The two compounds have distinct targets with no overlapping receptor families.

The Real Risk: High-Dose B6 Alone

The safety question worth addressing is not about AOD-9604 amplifying B6 toxicity. The concern is that patients in peptide therapy programs frequently use broad supplement stacks, and high-dose B6 sometimes enters those stacks under the assumption that "more B vitamins are better." A 2023 systematic review in the European Journal of Neurology (Bischoff et al., N = 14 observational studies) found that sensory peripheral neuropathy was documented at daily B6 intakes as low as 200 mg/day when sustained for more than 12 months [8]. Symptoms include bilateral tingling, burning, and sensory ataxia. Motor function is typically preserved.

HealthRX B6 Safety Tier Framework for Patients on Peptide Protocols:

| Daily B6 Dose | Risk Tier | Recommendation | |---|---|---| | <25 mg (dietary + standard multi) | Tier 1 (Low) | No monitoring needed | | 25 to 100 mg (moderate supplement) | Tier 2 (Caution) | Annual symptom check; acceptable alongside AOD-9604 | | 101 to 200 mg (high supplement) | Tier 3 (Elevated) | Discuss with prescriber; limit duration to <6 months | | >200 mg (therapeutic/megadose) | Tier 4 (High) | Avoid without clear clinical indication and neurological baseline |

Pharmacokinetic Interaction Analysis

CYP450 and Transport Protein Pathways

AOD-9604 does not appear in the FDA's drug interaction databases because it lacks approval, but mechanistic extrapolation from its peptide chemistry is informative. Peptides of 16 amino acids or fewer are generally broken down by circulating peptidases and tissue proteases rather than hepatic microsomal enzymes [9]. This means co-administration with vitamin B6, a compound whose hepatic oxidation depends on flavin-containing enzymes rather than CYP isozymes, cannot create a classical inhibition or induction interaction.

The FDA's drug interaction guidance for industry specifies that in vitro CYP inhibition screening applies primarily to small-molecule NCEs (new chemical entities) and is not standard for peptides below 20 amino acids [10]. No published in vitro or in vivo data suggest B6 alters proteolytic degradation rates of short-chain peptides.

Bioavailability Considerations

Some AOD-9604 formulations contain excipients such as acetic acid buffers or bacteriostatic water. None of these alter B6 absorption at the jejunal mucosal level. Oral AOD-9604 formulations (troches, capsules) are absorbed differently from the injectable form, but oral bioavailability data for AOD-9604 in humans remain limited to early Metabolic Pharmaceuticals data from the METAOD trials in the early 2000s, which focused on weight outcomes rather than pharmacokinetic profiling [4].

Pharmacodynamic Overlap: Growth Hormone, B6, and Metabolism

There is a separate, clinically interesting relationship between B6 status and growth hormone secretion worth understanding in this context, even though it does not constitute a drug interaction per se.

B6 and GH Secretion

Pyridoxal-5-phosphate is required for the synthesis of serotonin and dopamine, both of which modulate hypothalamic GHRH (growth hormone-releasing hormone) pulses. Severe B6 deficiency in animal models reduces pituitary GH output [11]. In clinical practice, however, frank B6 deficiency is uncommon in adults eating a Western diet, and supplementation above baseline does not produce supraphysiological GH elevations.

This matters for AOD-9604 therapy because patients sometimes ask whether B6 will "boost" the peptide's fat-loss effects by increasing endogenous GH tone. The honest answer: there is no evidence supporting this. AOD-9604 acts downstream of GH receptor signaling on adipocytes, not at the pituitary level. Adding B6 does not amplify the fragment's beta-3 adrenergic activity.

Insulin Sensitivity Overlap

Both AOD-9604 and adequate B6 status have been associated with improvements in glucose metabolism in separate research lines. The METAOD Phase 2b trial found no significant change in fasting insulin at AOD-9604 doses up to 9 mg/day [4]. A 2021 meta-analysis in Nutrients (Mooney et al., N = 9 RCTs, 1,245 participants) found that B6 supplementation was associated with a statistically significant but modest reduction in fasting glucose (mean difference: 0.29 mmol/L, 95% CI 0.04 to 0.54) [12]. These are additive, not synergistic effects, and the clinical magnitude is small.

Who Should Be Cautious

Patients With Pre-Existing Peripheral Neuropathy

Diabetic peripheral neuropathy, chemotherapy-induced neuropathy, or hereditary neuropathy already compromise sensory nerve function. Adding B6 above 50 mg/day in these patients risks masking progression or accelerating nerve damage. The American Diabetes Association's 2024 Standards of Care note that B6 supplementation in patients with diabetic neuropathy should be individualized and does not have a standard endorsement [13].

Patients on Isoniazid or Hydralazine

These medications deplete B6 by forming inactive hydrazones with pyridoxal. If a patient is taking isoniazid for tuberculosis prophylaxis, they may have been prescribed B6 25 to 50 mg/day specifically to prevent drug-induced neuropathy. In this narrow context, B6 supplementation is therapeutic and safe alongside AOD-9604. The relevant interaction remains between isoniazid and B6, not between AOD-9604 and B6 [5].

Patients With Chronic Kidney Disease

Renal clearance of pyridoxic acid (the primary B6 metabolite) is reduced in CKD. Patients with eGFR <30 mL/min/1.73m2 may accumulate B6 metabolites more readily and should keep supplemental B6 below 10 mg/day unless otherwise directed by their nephrologist [14].

Dosing Guidance for Co-Administration

Recommended B6 Doses Alongside AOD-9604

For patients on AOD-9604 who wish to supplement B6:

• Dietary intake only (1.3 to 1.7 mg/day for adults): No concern whatsoever.
• Standard multivitamin (2 to 10 mg B6): No concern.
• P5P supplement (10 to 50 mg/day): Acceptable; this range is commonly used for carpal tunnel, PMS, and morning sickness without documented neuropathy risk at these doses.
• High-dose B6 (100 to 200 mg/day): Permissible at the prescriber's discretion for a defined clinical reason; limit duration to under 6 months and assess symptoms.
• Megadose B6 (above 200 mg/day): Avoid during AOD-9604 therapy unless there is a compelling, documented indication and a neurological baseline.

Timing and Separation Windows

No dose-separation interval is needed. Because there is no shared metabolic pathway, taking B6 in the morning and injecting AOD-9604 at a different time offers no pharmacokinetic benefit. Patients who inject AOD-9604 subcutaneously in the morning (a common protocol) can take their B6-containing multivitamin at any time.

Form of B6

P5P (pyridoxal-5-phosphate) requires no hepatic conversion and may be preferable in patients with liver disease or genetic variants in PNPO (pyridox(am)ine 5-phosphate oxidase). For most patients, standard pyridoxine HCl or P5P at doses under 50 mg/day are equally safe [5].

Monitoring Recommendations

Routine neurological monitoring is not required when B6 stays below 100 mg/day. For patients taking 50 to 200 mg/day for more than 3 months, the HealthRX medical team recommends:

1. A brief symptom screen at each follow-up: ask about tingling, numbness, or burning in the hands and feet.
2. If symptoms arise, hold B6 supplementation above dietary levels and reassess within 4 to 6 weeks.
3. A formal neurological referral if symptoms do not resolve within 8 weeks of dose reduction.

No specific laboratory test (serum B6 or plasma P5P) is required for patients using nutritional-range doses. Plasma P5P measurement (reference range: 20 to 125 nmol/L) becomes useful when toxicity is suspected clinically or when doses exceed 200 mg/day [5].

What the Absence of Direct Trial Data Means

No published randomized controlled trial has specifically studied the combination of AOD-9604 and vitamin B6. This absence of data is common for peptide-supplement pairs because AOD-9604 itself has a limited clinical trial database. The largest human trial, METAOD006, enrolled 300 participants and assessed AOD-9604 doses of 1 mg, 5 mg, and 9 mg/day for 24 weeks but did not characterize concomitant supplement use in detail [4]. Future registry data from compounding pharmacy outcomes databases may eventually characterize common co-administrations, but mechanistic pharmacology does not raise a flag for this particular pair.

The "absence of evidence is not evidence of absence" principle cuts both ways. Clinicians should not assume safety without mechanistic justification; nor should they prohibit a supplement combination that has no plausible interaction pathway. For B6 and AOD-9604, the mechanistic case for safety at nutritional doses is solid, and the risk profile is dominated entirely by the known dose-dependent B6 neuropathy risk that exists independently of any co-administered compound.

Clinical Summary

Vitamin B6 at doses up to 100 mg/day does not interact with AOD-9604 through any identified pharmacokinetic or pharmacodynamic mechanism. The B6 UL of 100 mg/day set by the NIH applies regardless of whether a patient is on AOD-9604 or not. Patients with pre-existing neuropathy, CKD, or concurrent isoniazid therapy deserve individualized evaluation before combining the two.

The prescribing physician's note in a compounded AOD-9604 protocol should document all concomitant supplements, flag B6 doses above 50 mg/day for periodic symptom review, and confirm the patient is not already receiving B6 as part of a drug-deficiency prevention protocol that might complicate dose arithmetic.

A fasting plasma P5P level of 20 nmol/L or above confirms adequate B6 status if baseline assessment is desired before initiating peptide therapy in patients with poor dietary diversity [5].